KSM-66 600 mg AM (typical research dose):

• Onset over 1-2 weeks of consistent daily dosing — not acute.
• Felt as a "stress floor" — same external triggers, smaller internal amplitude. Less "I'm so anxious," more "that conversation should have rattled me and didn't."
• Sleep onset shortens by 5-15 min in most reports; deep-sleep architecture changes are inconsistent.
• Mild energy/recovery improvement, more noticeable in stressed/under-recovered users than in well-recovered ones.
• At 1200+ mg/day a non-trivial fraction of users report emotional blunting ("less anxious, less excited") — community-data anecdotes mirror this. Stay at 600 mg.

Sensoril 125-250 mg PM:

• More sedating profile; favored for evening dosing and sleep-onset insomnia.
• Anxiolytic effect arrives faster than KSM-66 — some users feel calm within 2-3 days.
• Less testosterone signal.

Shoden 120 mg PM:

• Strongest sleep-onset signal of the three; profile otherwise resembles Sensoril at lower mg.

Honest variability: ~10-15% of users feel nothing meaningful; ~10% report dose-dependent emotional flattening; ~5% get GI upset on empty stomach. The "ashwagandha killed my libido" reports are real but minority and dose-related.

Adaptogen-class tolerance is poorly characterized at the receptor level but well-described phenomenologically: the "stress floor" effect dulls in a non-trivial fraction of users by month 3-6. Community reports converge on this pattern even though no clinical trial has formally measured pharmacodynamic tolerance past 16 weeks. The mechanistic hypothesis is GABA-A receptor downregulation under chronic withanolide exposure plus HPA-axis adaptation — the cortisol set-point recalibrates and the "blunting effect" loses contrast.

Recommended cycle: 8 weeks on / 4 weeks off. This is the protocol most often cited in adaptogen practitioner literature and matches the duration of essentially every positive trial. Continuous use is plausibly fine — Sharma 2018 ran 8 weeks, Lopresti 2019 ran 16 weeks, and no trial has documented tolerance-driven loss of effect within those windows — but long-term safety data past 1 year is genuinely thin. Conservative default: cycle.

Reset: 4 weeks off appears to restore responsiveness in users who report fade. Combine with rhodiola-flip (run rhodiola during ashwagandha washout) for adaptogen continuity — keeps the HPA-modulation envelope active while letting withanolide-specific tolerance reset.

Withdrawal/discontinuation: No documented withdrawal syndrome. GABA-A binding affinity is too weak to support benzo-style dependence. Subjective stress and sleep may return to pre-cycle baseline within 1-2 weeks of stopping; this is reversal of effect, not withdrawal.

Dylan-specific: 8 wk KSM-66 → 4 wk washout running rhodiola only → reassess. If June bloodwork (cortisol, T, T3/T4) shows clear movement and subjective recovery/sleep markers have improved, repeat the cycle. If markers are flat at week 8, drop ashwagandha and redirect the slot to magnesium-glycinate dose-titration or sleep environment investment (blackout curtains, mouth tape, weighted blanket — all V4-adjacent moves with comparable expected value).

Synergistic

• rhodiola — different adaptogen mechanism (dopaminergic pro-energy vs HPA blunting). AM rhodiola + PM (or AM-with-meal) ashwagandha is the cleanest pairing. Already in Dylan's V4.
• l-theanine — additive calm without sedation overlap. Already in V4.
• magnesium glycinate — co-HPA support; magnesium independently lowers ACTH-driven cortisol output. Already in V4.
• fish oil / DHA — independent neuroprotective; complementary in athletic context.
• modafinil — opposing-axis pairing where modafinil drives the wake/dopaminergic side and ashwagandha buffers the cortisol/anxiety side. No known PK interaction.

Avoid stacking with

• Benzodiazepines, alcohol, high-dose THC, phenibut — additive GABAergic depression.
• Levothyroxine and other thyroid hormone replacement — monitor TSH closely; ashwagandha can shift the equilibrium toward over-replacement.
• Immunosuppressants (tacrolimus, MMF, biologics) — theoretical immune conflict; multiple case reports of flares.
• Strong sedative herbals (high-dose valerian, kava) — overlapping CNS depression.

Neutral / safe co-administration

Most V4/V5 stack compounds: NAC, citicoline, alpha-GPC, creatine, beta-alanine, D3/K2, omega-3, vitamin C, BPC-157, TB-500. No documented interaction with SSRIs/SNRIs.

• Sedatives + alcohol: Additive CNS depression. Clinically minor at standard doses, watch at >600 mg/day with co-use.
• Thyroid hormone replacement: Dose may need reduction; recheck TSH at 8-12 wk.
• Immunosuppressants: Theoretical immune-modulation conflict — case-report-level risk of autoimmune flare or transplant rejection. Avoid in transplant recipients.
• Antidiabetic drugs: Mild hypoglycemia potentiation at high doses; monitor BG in T1D/T2D users.
• Sedative-class anxiolytics (benzos, gabapentinoids): Additive; not contraindicated but lowers margin.
• Anesthesia: Theoretical risk of prolonged GABAergic depression; discontinue 2 wk before elective surgery.
• CYP3A4: Withanolides are CYP3A4 substrates; clinically meaningful interactions with CYP3A4 inhibitors/inducers are theoretical, not documented.

Ashwagandha PGx is poorly characterized — no clinical pharmacogenomic study has been published as of 2026. Withanolide metabolism is presumed to involve CYP3A4 (substrate) and conjugating UGT pathways, but human PK studies haven't dissected enzyme-by-enzyme contributions. Speculative implications from related literature:

• CYP3A4/3A5 expressers (~10% of Caucasians, higher frequency in some African populations) may clear withanolides faster — could push effective dose toward the upper end of 600 mg/day.
• COMT Val/Val vs Met/Met — no direct data, but the cortisol-blunting/HPA-axis interaction in high-anxiety Met/Met carriers is plausible. Worth a 1-2 wk subjective comparison.
• HLA associations with DILI — the Björnsson 2020 and Philips 2023 case series did not HLA-type their patients. Until a multi-center series with HLA typing publishes, no risk-stratification is possible. If a first-degree relative has had severe drug-induced liver injury from any cause, lower the threshold for ALT/AST checks.
• TPO antibody status — relevant for thyroid risk. Hashimoto's patients who are already on the slow road to hypothyroidism may benefit from the T3/T4 elevation; Graves patients can be tipped into thyrotoxicosis.

From standard 23andMe-class raw data plus Promethease, no actionable ashwagandha-specific inferences are currently extractable. Re-evaluate when Dylan's 23andMe results land (June 2026) — primarily for CYP3A4/3A5, COMT, and HLA-B/HLA-DR status as general "be cautious about herbal DILI" signals.

Dylan-specific: Nutricost KSM-66 600 mg, 120-cap bottle from Amazon — ~$20 — covers a full 8-wk cycle with leftover for a second run. Use the same brand both cycles to control standardization variance.

Baseline (before starting):

• AM cortisol (serum or 4-point salivary)
• Total testosterone, free testosterone, SHBG (men)
• TSH, free T3, free T4
• ALT, AST, ALP, bilirubin
• CBC + comprehensive metabolic panel
• Subjective stress (PSS-10), anxiety (GAD-7), sleep (PSQI) baselines

Week 4 check (optional):

• Subjective stress + sleep VAS only — if no movement, consider stopping early.

Week 8 (mandatory):

• AM cortisol, total + free T, TSH, ALT/AST.
• Compare PSS/GAD-7/PSQI to baseline.

Post-cycle (after 4-wk washout):

• Same panel to assess whether effects persist or were dose-dependent.

For Dylan: Bake into the June 2026 bloodwork window — cortisol/T/TSH already on his planned panel. Add ALT/AST if not present.